Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA nanoparticle
- Development stage
- Preclinical
- Lead developer
- Optimum Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Optimum Therapeutics is researching a platform for the delivery of small interfering RNA (siRNA) using nanoparticle technology, specifically intended for the treatment of solid tumors. The program is currently in the preclinical stage and is designed to be integrated with the company's proprietary 'Tumor Priming Technology.' This technology aims to improve the penetration of nanomedicines into tumors by using 'primers'—such as paclitaxel nanoparticles (PNP) or suramin—to modify the tumor microenvironment and reduce interstitial fluid pressure. While the company has published research on siRNA delivery and its enhancement via tumor priming, no specific drug candidates or molecular mRNA targets have been formally named in a structured pipeline.
- Other names
- siRNA deliverysiRNA nanoparticles
02
Targets
Kirsten rat sarcoma viral oncogene homolog mRNA
Beyond the preview
Go deeper on siRNA nanoparticle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA nanoparticle.